Trial reportThe neuroradiology journal2014
Quantitative serial T2 relaxometry: a prospective evaluation in solitary cerebral cysticercosis.
Trial report in The neuroradiology journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- Letter to the editor - quantitative serial t2 relaxometry and cerebral cysticercosis.The neuroradiology journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the evolution of quantitative T2 relaxometry values on serial MRI in patients with a solitary cerebral cysticercal lesion (SCCL), and determine whether albendazole therapy affects T2 relaxation (T2R) values. Patients with new-onset seizures and MRI-confirmed SCCL were randomized to treatment with albendazole and antiepileptics ("treatment group") or antiepileptics only ("controls"). Serial MRI including T2 relaxometry was performed at baseline, three, six, 12, and 24 months. Of 123 patients recruited, 81 had more than three MRI scans (treatment group: 37; controls: 44; 58 patients had five scans). The lesion wall at baseline showed a mean T2R value of 152.3 ms, centre 474.9 and perilesional parenchyma 338.5 ms. These were significantly higher than those from normal parenchyma (114 ms). Over time, most sharply in the initial three months, T2R values fell but even at 24 months, they remained above those from normal parenchyma. A slight increase in T2R values from the lesion centre at six months was thought to represent the initiation of gliosis. In the treatment group, T2R values approached normal at 24 months, while controls had persistently higher T2R values. The decline in T2R values at six months was more prominent in the treatment group. T2R values at baseline and at three months differed significantly depending on the stage of the lesion, being higher in stage 2 SCCL. T2R values from SCCL declined over 24 months, being significantly higher in earlier stages of degeneration. A mild increase after six months may be due to the initiation of gliosis. T2R values appear to decline faster in patients who receive albendazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.